WVSHP Logo Contact Information
News & Events

News from WVSHP

ASHP and ACPE revised guidelines ASHP and the Accreditation Council for Pharmacy Education (ACPE) just released revisions to the Accreditation Standards for Pharmacy Technician Educat (Click for more...) 2019 Spring Meeting - Save the date SAVE THE DATE for the Spring Meeting 2019 April 26th and 27th, 2019 Embassy Suites, Charleston, WV (Click for more...)

News from elsewhere...
Updated guideline released on use of testosterone therapy for hypogonadism 8/14/2018 1:02:27 PM Key Point:The Endocrine Society released an updated clinical practice guideline on use of testosterone therapy for men with hypogonadism in the Journal of Clinical Endocrinology and Metabolism. The guideline recommends that men with symptoms of low testosterone be tested and treatment be given to hypogonadal men ( (Click for more...) Nearly one-third of children use dietary supplements 8/14/2018 1:00:44 PM Key Point:An analysis of data from the National Health and Nutrition Examination Surveys (NHANES) from 2003 to 2014 published in JAMA Pediatrics found that approximately 33% of children and young adults (aged 0–19 y) use dietary supplements that range from multivitamins to melatonin to omega-3 fatty acids. (Click for more...) Four new medicines cleared for use on NHS Scotland 8/14/2018 5:58:38 AM The Scottish Medicines Consortium has approved funding for four newly licensed medicines, expanding NHS treatments options in Scotland for ovarian cancer, lung cancer, urea cycle disorders and acute hereditary angioedema. (Click for more...) Xolair deemed ‘breakthrough’ therapy for food allergies 8/14/2018 5:53:13 AM Roche/Novartis’ Xolair has been awarded breakthrough status in the US for treatment of severe allergic reactions after accidental exposure to foods allergens. (Click for more...) Draft guidelines reject NHS funding for Biogen’s Spinraza 8/14/2018 5:46:29 AM The National Institute for Health and Care Excellence is not recommending NHS use of Biogen’s Spinraza for the rare genetic disorder spinal muscular atrophy (SMA) at this time. (Click for more...) Motif Bio’s antibiotic granted US priority review 8/14/2018 5:40:38 AM US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI). (Click for more...) Orchard raises $150m to advance gene therapies 8/14/2018 5:36:36 AM UK-American biotech Orchard Therapeutics has raised $150 million to fuel development of its gene therapy pipeline. (Click for more...) Bowel cancer screening to start 10 years earlier 8/13/2018 5:47:25 AM Bowel cancer screening in England and Wales is to start a decade earlier in a drive to pick up more cases of the disease at an earlier stage, the government has confirmed. (Click for more...) Amicus’ Galafold wins US approval 8/13/2018 5:41:41 AM Amicus Therapeutics’ Galafold has been approved in the US as the first oral medication for the treatment of adults with Fabry disease. (Click for more...) Astellas buys UK group Quethera 8/13/2018 5:39:05 AM Astellas has acquired Cambridge, UK-based Quethera, a gene therapy group focused on the development of novel treatments for ocular disorders, such as glaucoma. (Click for more...) Alnylam’s novel RNA therapy Onpattro wins nod for hATTR amyloidosis 8/13/2018 5:37:04 AM The US Food and Drug Administration has approved Alnylam’s RNAi therapeutic Onpattro for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. (Click for more...) Pharma lacks engagement with mental health groups: report 8/10/2018 9:39:34 AM Janssen ranks first in new survey of pharma's reputation among mental health patient groups (Click for more...) Medical & Scientific Advisors to get the recognition they deserve 8/10/2018 8:26:47 AM PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events. (Click for more...) New charity award to focus on real challenges 8/10/2018 8:03:42 AM The PharmaTimes Communications Team of the Year competition is the only pharma industry awards that tests the competencies and potential of communications agency teams, benchmarking talent agency side. This year sees the introduction of a new 'Charity Challenge', which in partnership with Beating Bowel Cancer and Bowel Cancer UK, will focus on a real life scenario for the first time. (Click for more...) Embracing the importance of cross functional working 8/10/2018 7:59:50 AM Director of policy and communications at MSD and executive steering group member Harry Brady looks at how the PharmaTimes Marketer and Communications Team of the Year competitions have evolved to embrace the importance of cross-functional working and the value of great healthcare communications in the marketing mix. (Click for more...) Artios Pharma raises £65m to develop DDR therapies 8/10/2018 6:45:39 AM Oversubscribed financing includes investment from Pfizer and Novartis (Click for more...) Merck profits decline but new drugs maintain sales growth 8/10/2018 5:27:31 AM Strong performances for Mavenclad and Bavencio (Click for more...) Denosumab is a good option for patients receiving glucocorticoids 8/6/2018 2:39:44 PM Key Point:Use of denosumab (Prolia—Amgen) for 12 months was shown to be both noninferior and superior to risedronate on select bone mineral density endpoints for patients newly initiating glucocorticoids or those continuing therapy, according to results of a trial published in The Lancet Diabetes and Endocrinology. (Click for more...) DTaP vaccines are safe, but take care to prevent vaccination-related errors 8/6/2018 2:06:36 PM Key Point:An in-depth review of data from the Vaccine Adverse Event Reporting System (VAERS) on DTaP-based vaccines over a 19-year period showed no new or unexpected safety signals, with the most common adverse events being injection-site reactions and fever. Nonserious vaccination errors were also identified as an issue. (Click for more...) Fingolimod and dimethyl fumarate appear to have similar efficacy for MS 7/30/2018 11:36:10 AM Key Point:Use of fingolimod (Gilenya—Novartis) or delayed-release dimethyl fumarate (Tecfidera—Biogen) for patients with relapsing-remitting multiple sclerosis (RRMS) appears to have similar efficacy for treatment-naive patients, but use of fingolimod appears to have superior efficacy in treatment-experienced patients, according to results of an observational study published in Neurology. (Click for more...) Depression may result from adverse medication effects 7/30/2018 11:18:47 AM Key Point:A U.S. population–based survey conducted over a 10-year period showed that a little more than one-third of patients used medications that list depression as a potential adverse effect, and the occurrence of depression was higher among patients who used multiple agents. compared with those not using such medications, according to a report in JAMA. (Click for more...) Metformin and the risk of acidosis in patients with kidney disease 7/24/2018 10:25:44 AM Key Point:Use of metformin in patients with an estimated glomerular filtration rate (eGFR) between 30 mL/min/1.73 m2 and 45 mL/min/1.73 m2 did not result in an increased risk of incident acidosis compared with alternative diabetes treatments, according to data from two large retrospective cohort analyses. (Click for more...) Nicotine preloading may be beneficial for smoking cessation 7/24/2018 9:50:54 AM Key Point:Use of a nicotine patch worn for 4 weeks before attempting to quit smoking resulted in higher odds of abstinence at 4 weeks, 6 months, and 12 months compared with no nicotine preloading, but only after adjustments were made for subsequent varenicline use in the two groups. (Click for more...) Pharmacogenetic-based decision tools are not interchangeable 7/16/2018 11:44:26 AM Key Point:A comparison of four commercially available pharmacogenetic-based decision tools in patients with major depressive disorder (MDD) and numerous treatment failures showed that genotype and predicted phenotype agreement varied substantially, as did medication recommendations, indicating these tests cannot be considered equivalent or interchangeable. (Click for more...) Drug interactions are common among older adults receiving antiretroviral therapies 7/16/2018 11:29:25 AM Key Point:A cross-sectional observational study published in the Journal of Acquired Immune Deficiency Syndromes involving 744 patients with HIV receiving antiretroviral treatment and at least one nonantiretroviral medication showed that more than one-half of these patients had at least one or more potential drug–drug interactions (DDIs), with a higher risk of interactions observed for those receiving five or more medications. (Click for more...)
Copyright© 2018 West Virginia Society of Health System Pharmacists. All rights reserved.